Evolent Health (EVH) Lifted to “Hold” at ValuEngine

Evolent Health (NYSE:EVH) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Friday.

A number of other research firms also recently commented on EVH. Zacks Investment Research raised shares of Evolent Health from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Canaccord Genuity dropped their price objective on shares of Evolent Health from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Wednesday, February 28th. Wells Fargo dropped their price objective on shares of Evolent Health from $27.00 to $20.00 and set an “outperform” rating for the company in a research note on Wednesday, February 28th. Finally, Jefferies Group set a $22.00 price objective on shares of Evolent Health and gave the company a “buy” rating in a research note on Tuesday, February 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the stock. Evolent Health presently has an average rating of “Buy” and an average target price of $25.33.

NYSE EVH opened at $18.50 on Friday. Evolent Health has a 12 month low of $10.30 and a 12 month high of $27.50. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.85 and a quick ratio of 2.85. The stock has a market cap of $1.29 billion, a PE ratio of -26.43 and a beta of 1.04.

Evolent Health (NYSE:EVH) last posted its quarterly earnings data on Wednesday, May 9th. The technology company reported $0.02 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.06. Evolent Health had a negative net margin of 12.11% and a negative return on equity of 2.19%. The company had revenue of $139.70 million during the quarter, compared to the consensus estimate of $140.89 million. During the same quarter in the prior year, the company posted ($0.14) EPS. The company’s quarterly revenue was up 31.5% compared to the same quarter last year. analysts expect that Evolent Health will post -0.34 earnings per share for the current fiscal year.

In related news, Director Unitedhealth Group Inc sold 3,040,000 shares of the stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $13.70, for a total transaction of $41,648,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Seth Blackley sold 64,398 shares of the stock in a transaction that occurred on Thursday, May 10th. The stock was sold at an average price of $17.63, for a total transaction of $1,135,336.74. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,189,994 shares of company stock valued at $44,245,316. Corporate insiders own 8.79% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new stake in Evolent Health during the 4th quarter worth approximately $144,000. Quantbot Technologies LP increased its position in Evolent Health by 111.4% during the 1st quarter. Quantbot Technologies LP now owns 10,815 shares of the technology company’s stock worth $154,000 after purchasing an additional 5,698 shares in the last quarter. Virtu Financial LLC acquired a new stake in Evolent Health during the 4th quarter worth approximately $172,000. Fox Run Management L.L.C. acquired a new stake in Evolent Health during the 4th quarter worth approximately $175,000. Finally, Teacher Retirement System of Texas acquired a new stake in Evolent Health during the 4th quarter worth approximately $251,000.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply